People: Albany Molecular Research Inc (AMRI.OQ)
AMRI.OQ on NASDAQ Stock Exchange Global Select Market
13.06USD
1:20pm EDT
13.06USD
1:20pm EDT
Price Change (% chg)
$0.36 (+2.83%)
$0.36 (+2.83%)
Prev Close
$12.70
$12.70
Open
$12.64
$12.64
Day's High
$13.14
$13.14
Day's Low
$12.61
$12.61
Volume
28,824
28,824
Avg. Vol
121,451
121,451
52-wk High
$13.84
$13.84
52-wk Low
$2.93
$2.93
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
William Marth |
58 | 2013 | Chairman of the Board |
Thomas D' Ambra |
57 | 2013 | President, Chief Executive Officer, Director |
Michael Nolan |
48 | 2012 | Chief Financial Officer, Vice President, Treasurer |
Steven Hagen |
52 | 2012 | Senior Vice President - Pharmaceutical Development and Manufacturing |
Bruce Sargent |
59 | Senior Vice President - Drug Discovery | |
Lori Henderson |
51 | 2011 | Vice President, General Counsel, Secretary |
Richard Saffee |
2013 | Vice President and General Manager - Large Scale Manufacturing | |
Takeshi Yura |
2013 | Vice President - Discovery and Development Services, Asia | |
Una Ryan |
71 | 2010 | Lead Independent Director |
Veronica Jordan |
62 | 2006 | Independent Director |
Gabriel Leung |
51 | 2010 | Independent Director |
Kevin O' Connor |
58 | 2000 | Independent Director |
Arthur Roth |
73 | 2003 | Independent Director |
Biographies
| Name | Description |
|---|---|
William Marth |
Mr. William S. Marth has been appointed as Chairman of the Board of Albany Molecular Research, Inc., effective June 5, 2013. Mr. Marth was appointed to the AMRI Board of Directors in 2012, joining Veronica G. H. Jordan, Ph.D.; Gabriel Leung; Kevin O'Connor; Arthur J. Roth; and Una S. Ryan, O.B.E., Ph.D. Mr. Marth, formerly President and Chief Executive Officer of Teva - Americas, retired from Teva in 2012. He had previously served as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and prior to that as President and Chief Executive Officer of Teva USA. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA. Mr. Marth, who earned his B.Sc. in Pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University, is a licensed pharmacist and serves on various other boards and committees, including The University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins' Project RESTORE. In addition, Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010. |
Thomas D' Ambra |
Dr. Thomas E. D' Ambra, Ph.D., is President, Chief Executive Officer, Director of Albany Molecular Research Inc. He co-founded the Company in 1991 and has served as Company's Chairman of the Board and Chief Executive Officer since inception. Dr. D’Ambra was appointed the additional title of President in February 2003, a position he also held from 1991 – 1998. Prior to co-founding the Company, Dr. D’Ambra served as the Vice President, Chemistry and co-founder of Coromed, Inc., a traditional development contract research organization, from 1989 to 1991 and Group Leader and Senior Research Chemist with Sterling Winthrop, Inc., a pharmaceutical company, from 1982 to 1989. Dr. D’Ambra holds a B.A. degree in chemistry from the College of the Holy Cross and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology. |
Michael Nolan |
Mr. Michael M. Nolan has been appointed as Chief Financial Officer, Vice President, Treasurer of Albany Molecular Research Inc., effective September 17, 2012. Mr. Nolan was most recently Vice President, Finance, Financial Planning and Analysis at the Delaware North Companies, headquartered in Buffalo, N.Y. From 2009 through early 2012, Mr. Nolan was Vice President, Finance, Analytical Instruments Group at Thermo Fisher Scientific, Inc. where he was responsible for the global financial operations of a portfolio with revenue of $3 billion operating across three divisions with 15 business units, 41 plant sites and 9,700 employees. Prior to Thermo Fisher Scientific, Mr. Nolan held positions of increasing responsibility at ALCAN, which was later acquired by Rio Tinto Plc. While at Rio Tinto Plc., Mr. Nolan was accountable for the integration of 13 global ALCAN and Rio Tinto Plc. functions, including legal, company secretarial, business development and all finance functions including both the corporate and business teams. Mr. Nolan began his career in 1989 at E.I. du Pont de Nemours Company and received his MBA from The University of Windsor and a B.A. in Economics from The University of Western Ontario. |
Steven Hagen |
Dr. Steven R. Hagen, Ph.D, has been appointed as Senior Vice President - Pharmaceutical Development and Manufacturing of Albany Molecular Research Inc., effective 22 October 2012. Dr. Hagen joined AMRI in 2005 as senior director of analytical quality services and has risen to positions of increasing responsibility. In 2006, Dr. Hagen was promoted to vice president for quality and analytical chemistry and was responsible for Analytical Chemistry, Quality Assurance and Regulatory Affairs for all AMRI locations. In 2008, Dr. Hagen was promoted to vice president of pharmaceutical development and manufacturing. Prior to AMRI, he spent more than 10 years at Pfizer in positions of increasing responsibility culminating in director of analytical research and development at Pfizer's Global Research and Development Division. Before Pfizer, he managed the analytical activities at Ribi ImmunoChem Research, Inc. in support of R&D, production and quality control. Dr. Hagen earned a Ph.D. in biochemistry and a Master's degree in botany, both from the University of Idaho, as well as a B.A. in biology from Lawrence University. |
Bruce Sargent |
Dr. Bruce J. Sargent, Ph.D., is Senior Vice President - Drug Discovery of Albany Molecular Research Inc. In this position he holds responsibility for AMRI’s global drug discovery operation embodying biology, chemistry and DMPK groups located in the US, Singapore, India and Hungary and for AMRI’s own R&D portfolio. Previously Dr. Sargent was Vice President of Discovery R&D, in which position he established AMRI’s internal drug discovery group and took responsibility for AMRI’s in vitro biology, metabolism and biotransformations and natural product operations. During his time in that role, AMRI announced a strategic license deal of its CNS program and several strategic natural product collaborations. Dr. Sargent joined AMRI in 2001, as Director of Medicinal Chemistry and held responsibility for several customer relationships, covering a wide range of therapeutic approaches. Prior to AMRI, Dr. Sargent worked for over 20 years as a drug discovery scientist at Boots Pharmaceuticals in the UK (later Knoll Ltd., the UK division of BASF Pharma), where he became Head of Chemistry. While at Boots Pharmaceuticals, Dr. Sargent managed research projects in several therapeutic areas, with a particular focus on CNS and metabolic disease. In addition to scientific and departmental management responsibilities, Dr. Sargent had strategic involvement in portfolio, licensing, M&A and collaborative activities. Dr. Sargent’s involvement at Knoll was international, managing groups in Spain and India and collaborating with groups in Germany and the USA. Dr. Sargent is a member of the American Chemical Society and a Fellow of the Royal Society of Chemistry. He obtained B.A. and M.A. degrees in Natural Sciences from the University of Cambridge, a second B.A. degree in biology and computer science from the Open University and his Ph.D. from the University of Manchester. |
Lori Henderson |
Ms. Lori M. Henderson, Esq., is Vice President, General Counsel, Secretary of Albany Molecular Research Inc. She joined AMRI in 2011 and is responsible for all of AMRI’s legal activities for the Company’s locations worldwide, including the United States, Europe and Asia. She also serves as the corporate secretary. From 2008 to 2010, she served as general counsel, corporate secretary and chief administrative officer for Rand Worldwide, Inc. where she oversaw the legal, human resource and IT departments of this technology company. Ms. Henderson was part of the management team that led the transaction between Rand Worldwide and Avatech Solutions Inc. From 1999 through 2008 she held increasing positions of responsibility at Moldflow Corporation and most recently was general counsel, corporate secretary and chief administrative officer for Moldflow Corporation, a company operating in the CAD/CAE business with global operations. At Moldflow, Ms. Henderson was responsible for the legal, human resources and IT functions at the Company, and was part of the management team that completed the sale of Moldflow to Autodesk in June 2008. Ms. Henderson also served as corporate counsel and secretary at C.P. Clare Corporation and prior to that was an associate at Goodwin Procter LLP, specializing in corporate transactions. Ms. Henderson holds a B.A. from Gordon College and a J.D. from George Washington University. |
Richard Saffee |
Mr. Richard A. Saffee has been appointed as Vice President and General Manager - Large Scale Manufacturing of Albany Molecular Research, Inc. Before coming to AMRI, Mr. Saffee led manufacturing activities for multiple U.S.-based operations for Pfizer Global Manufacturing. and Pfizer Global Human Health. Prior to the acquisition of Parke-Davis by Pfizer, Mr. Saffee held roles of increasing responsibility at Parke-Davis including Director of Chemical Manufacturing and Area Production Manager. He has knowledge in the areas of chemical manufacturing, technology transfer, regulatory compliance and quality standards, purchasing and materials management and managing global relationships. He is also trained in Lean Six Sigma techniques. Mr. Saffee earned a Master's degree in Business Administration from Grand Valley State University in Allendale, Michigan and a Bachelor's of Science degree in Chemical Engineering from the University of Michigan in Ann Arbor, Michigan. |
Takeshi Yura |
Dr. Takeshi Yura, Ph.D., has been appointed as Vice President - Discovery and Development Services, Asia of Albany Molecular Research, Inc., effective February 25, 2013. Dr. Yura joined AMRI in January 2011 and most recently served as Senior Director of Drug Discovery services in Singapore, the chemistry and biology teams of AMRI's flagship Asian integrated drug discovery operations. Effective immediately, Dr. Yura has also assumed leadership of AMRI's Discovery and Development efforts at AMRI's Hyderabad, India site. Dr. Yura brings to this role more than 22 years of scientific and leadership experience in discovery research, project management and business development. Before joining AMRI, he was a director at Dishman Japan Ltd., responsible for sales and all business development activities for contract manufacturing services. Before that, he served as discovery chemistry research head at Pfizer Japan, dedicated primarily to the areas of pain and gastrointestinal drug discovery. Prior to Pfizer, he served as section head, medicinal chemistry at Bayer Yakuhin in Japan focused on urology and asthma. He has held additional scientific roles at both Ciba Geigy Japan and Tanabe Seiyaku. Dr. Yura obtained a Ph.D. in synthetic organic chemistry at the University of Tokyo, working with Professor Teruaki Mukaiyama until his retirement and with Professor Koichi Narasaka. He also holds an M.B.A. from the Temple University Tokyo. |
Una Ryan |
Ms. Una S. Ryan Ph.D., OBE, is Lead Independent Director of Albany Molecular Research Inc., since October 2006. She is currently President of Diagnostics for All, a non-profit focused on low-cost and easy-to-use diagnostics for the developing world. Previously, she was President and CEO of Waltham Technologies, Inc. a company in the Clean Water-Clean Energy business. Concurrently, she holds the position of research professor of medicine at Boston University School of Medicine. Prior to joining Waltham, she was President and CEO of AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) and also a member of its Board of Directors, 1993 to 2007. Prior to AVANT, she was director of Health Sciences at Monsanto Company, 1990 to 1993. Before that, she held a number of positions in academia, including research professor of surgery at Washington University School of Medicine in St. Louis, 1990 to 1994; and professor of medicine at the University of Miami School of Medicine, 1972 to 1989. Dr. Ryan graduated from England’s Bristol University, with B.Sc. degrees in Zoology, Chemistry, and Microbiology. In 2009 she received an Honorary D.Sc. from Bristol University. She received a Ph.D. from Cambridge University. Dr. Ryan has served on several private company boards and industry trade organizations, including the board of BIO, and is past chair of the Massachusetts Biotechnology Council. In 2002, she was awarded the Order of the British Empire (O.B.E.) for her work to foster and promote biotechnology. |
Veronica Jordan |
Dr. Veronica G. H. Jordan, Ph.D., is Independent Director of Albany Molecular Research Inc., since October 2006. Dr. Jordan is an independent consultant providing senior management experience to companies developing novel healthcare products and services. Previously she served as president, chief executive officer and board member of Medelle Corporation, a medical device company in the women’s health area. Prior to joining Medelle, Dr. Jordan served 14 years, 1987 – 2001, as Senior Vice President and before that Vice President at Parexel International Corporation, a global contract pharmaceutical outsourcing organization that provides clinical research, medical marketing and consulting services. Dr. Jordan worked at Biogen Incorporated (now Biogen Idec), 1981 – 1987, as product manager and was ultimately promoted to director of marketing and business development. In 1979, Dr. Jordan began her industry career in the R&D labs at Baxter International after earning a B.Sc. in Biochemistry from Cambridge University and a Ph.D. in Biochemistry/Cell Biology from Oxford University, and completing a postdoctoral research fellowship at the Dana Farber Cancer Institute. |
Gabriel Leung |
Mr. Gabriel S. Leung is Independent Director of Albany Molecular Research Inc., since November 2010. In August 2011, Mr. Leung was named Executive Vice Chairman of the board of Novocure, Ltd., a medical device company pioneering the fourth cancer treatment modality. From 2003 through 2010 Mr. Leung held executive positions at OSI Pharmaceuticals, most recently as executive vice president and president of the Pharmaceutical Business at OSI. While at OSI he was responsible for the entire oncology business unit, including Research and Development, Commercial, Medical Affairs and Business Development. Mr. Leung was instrumental in the record-setting launch of oncology drug Tarceva by OSI in 2004 and the acquisition of OSI by Astellas in 2010. Prior to OSI, Mr. Leung held positions at Pharmacia, most recently as Group VP, Global Prescription Business & Head, Global Oncology Franchise; and Bristol-Myers Squibb, most recently as Senior Director, US Oncology Marketing and Sterling Drug Inc. Mr. Leung has served as an advisor to the National Cancer Institute and has served for over ten years under former President George H.W. Bush as an active member of C-Change, a national initiative aiming to eliminate cancer as a public health concern. He holds a B.S. in Pharmacy from the University of Texas at Austin and a M.S. in Pharmacy from University of Wisconsin-Madison. |
Kevin O' Connor |
Mr. Kevin O' Connor is Independent Director of Albany Molecular Research Inc., since March 2000. Mr. O’Connor has served as Chief Executive Officer of Tech Valley Communications, a telecommunications company, since July 2000. Mr. O’Connor previously served as the President of the Center for Economic Growth, Inc., a business-sponsored economic development organization, from February 1992 through July 2000. Mr. O’Connor also served as a Deputy Commissioner for the New York State Department of Economic Development from September 1987 to February 1992, as a Program Associate for the New York State Governor’s Office from July 1984 to September 1987 and held various positions in the New York State Division of the Budget and the New York State Department of Health from January 1980 to July 1984. Mr. O’Connor also serves as a director of several private companies and non-profit organizations. Mr. O’Connor holds a B.A. degree in history and a Masters degree in public administration from the State University of New York College in Brockport. |
Arthur Roth |
Mr. Arthur J. Roth, CPA, is Independent Director of Albany Molecular Research Inc., since October 2003. Mr. Roth previously served as commissioner of the New York State Department of Taxation and Finance from 1999 to 2003. Prior to his appointment as Commissioner, Mr. Roth was Deputy Commissioner for Operations, New York State Department of Taxation and Finance from 1996 until 1999. Mr. Roth was a senior consulting director with Coopers and Lybrand from 1992 to 1996 and a founder and managing director of Roth Nobis & Company, an accounting firm serving the manufacturing and service industries, from 1968 to 1992. Mr. Roth serves as a director for MVP Healthcare and also serves as director for several non-profit companies. Mr. Roth served on the Board of Directors and as the Chair of the Audit Committee of First Albany Capital Inc. from October 2003 until August 2006. Mr. Roth is a certified public accountant and holds a B.A. degree from Syracuse University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
William Marth |
-- |
Thomas D' Ambra |
4,090,120 |
Michael Nolan |
967,623 |
Steven Hagen |
578,484 |
Bruce Sargent |
508,177 |
Lori Henderson |
561,545 |
Richard Saffee |
-- |
Takeshi Yura |
-- |
Una Ryan |
-- |
Veronica Jordan |
-- |
Gabriel Leung |
-- |
Kevin O' Connor |
-- |
Arthur Roth |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
William Marth |
0 | 0 |
Thomas D' Ambra |
183,436 | 3,416,673 |
Michael Nolan |
0 | 0 |
Steven Hagen |
0 | 0 |
Bruce Sargent |
0 | 0 |
Lori Henderson |
0 | 0 |
Richard Saffee |
0 | 0 |
Takeshi Yura |
0 | 0 |
Una Ryan |
0 | 0 |
Veronica Jordan |
0 | 0 |
Gabriel Leung |
0 | 0 |
Kevin O' Connor |
0 | 0 |
Arthur Roth |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
CABLE STUART M |
30,000 | $12.47 |
CABLE STUART M |
30,000 | $12.00 |
RYAN UNA S |
1,434 | $10.46 |
ROTH ARTHUR J |
396 | $10.46 |
MARTH WILLIAM S |
2,868 | $10.46 |
JORDAN VERONICA G H |
1,434 | $10.46 |
O CONNOR KEVIN |
1,434 | $10.46 |
MARTH WILLIAM S |
10,000 | $10.23 |
SARGENT BRUCE J |
454 | $0.00 |
D AMBRA THOMAS E |
6,667 | $0.00 |
HENDERSON LORI M |
1,458 | $0.00 |
HAGEN STEVEN R |
1,250 | $0.00 |
HAGEN STEVEN R |
454 | $0.00 |
SARGENT BRUCE J |
1,250 | $0.00 |
HENDERSON LORI M |
477 | $0.00 |
HAGEN STEVEN R |
800 | $11.26 |
SARGENT BRUCE J |
7,500 | $2.93 |
SARGENT BRUCE J |
7,500 | $10.97 |
D AMBRA CONSTANCE M |
7,000 | $0.00 |
D AMBRA THOMAS E |
7,000 | $0.00 |
HAGEN STEVEN R |
1,200 | $10.40 |
SARGENT BRUCE J |
258 | $9.91 |
HAGEN STEVEN R |
180 | $9.91 |
HAGEN STEVEN R |
249 | $9.98 |
SARGENT BRUCE J |
256 | $9.98 |

